LS9

LS9 Planning Brazil’s Biggest Plant to Make Biofuels, Chemicals

LS9 Planning Brazil’s Biggest Plant to Make Biofuels, Chemicals

July 8, 2011

LS9 Inc., a closely held U.S. biotechnology company, may build Brazil’s biggest biofuel and specialty chemicals factory as more companies seek to produce new products from sugar cane, the world’s cheapest fuel crop.

The company is planning a facility may be able to produce as much as 200 million gallons (758 million liters) of fuel and chemicals a year, more than two-thirds bigger than Brazil’s largest biofuels plant, South San Francisco, California-based LS9’s Chief Executive Officer Edward Dineen said in an interview.

LS9

LS9 Announces Collaboration with MAN Latin America To Test LS9's UltraClean Diesel in Brazilian Fleet

LS9 Announces Collaboration with MAN Latin America To Test LS9's UltraClean Diesel in Brazilian Fleet

July 7, 2011

SAO PAULO, BRAZIL and SOUTH SAN FRANCISCO, CA - July 7, 2011 - LS9, Inc., a technology leader in the development of sustainable products, announced that it has begun a collaboration with MAN Latin America, a leading Brazilian engineering and vehicles manufacturing company, to test LS9's renewable diesel in both stationary engines and operational fleet vehicles in Brazil.

LS9

LS9 Extends Research In Synthetic Hydrocarbon Products with Chevron

LS9 Extends Research In Synthetic Hydrocarbon Products with Chevron

July 11, 2011

SOUTH SAN FRANCISCO, CA - July 11, 2011 - LS9 Inc., a technology leader in the development of sustainable products, today announced it will carry out a second phase of research with Chevron Technology Ventures, a division of Chevron U.S.A, Inc. This program is directed at further improving LS9's platform technology to produce specific pure hydrocarbon products. This second phase follows Chevron's initial testing and evaluation of LS9's technology solution.

RISING STAR: Flagship's Berry Harkens Back To Venture Capital's Roots

RISING STAR: Flagship's Berry Harkens Back To Venture Capital's Roots

July 1, 2011

From the July issue of Private Equity Analyst

While studying at Massachusetts Institute of Technology and Harvard Medical School, Flagship Ventures Partner David Berry knew he had several career options. Although he wasn't sure which path to take, he was fairly certain about what he didn't want.

Concert Pharmaceuticals, Inc.

Concert Pharmaceuticals Announces Advancement of Novel Drug Candidates in Kidney Disease and Spasticity

Concert Pharmaceuticals Announces Advancement of Novel Drug Candidates in Kidney Disease and Spasticity

June 20, 2011

LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. announced today the advancement of two programs from its DCE Platform™ (deuterated chemical entity platform). CTP-499 is progressing into Phase 2 clinical trials for diabetic nephropathy and C-21191 has been selected as a lead candidate for spasticity.

Concert Pharmaceuticals, Inc.

Concert Announces Milestone Achievement in GlaxoSmithKline Collaboration

Concert Announces Milestone Achievement in GlaxoSmithKline Collaboration

June 20, 2011

LEXINGTON, Mass.--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. today announced that it has achieved a milestone in its strategic alliance with GlaxoSmithKline (GSK) for its HIV protease inhibitor (HIV-PI) development program, resulting in a $4 million milestone payment to Concert. The strategic alliance with GSK was formed in 2009. In the HIV development program a number of deuterium modified-versions of atazanavir were evaluated preclinically, and a subset was selected for further testing in early human clinical studies.

Selecta Biosciences, Inc.

The Juvenile Diabetes Research Foundation and Selecta Biosciences Enter Research Collaboration for Vaccines for Type 1 Diabetes

The Juvenile Diabetes Research Foundation and Selecta Biosciences Enter Research Collaboration for Vaccines for Type 1 Diabetes

June 9, 2011

New York, NY, and Watertown, MA – June 9, 2011 – The Juvenile Diabetes Research Foundation (JDRF) and Selecta Biosciences, Inc. announced today that they have established a research collaboration to support Selecta's development of a vaccine technology, which may subsequently help to better treat and potentially prevent type 1 diabetes.

AVEO Pharmaceuticals, Inc.

AVEO Pharmaceuticals Enters into Worldwide License Agreement with Centocor Ortho Biotech to Develop and Commercialize RON-Targeted Antibodies

AVEO Pharmaceuticals Enters into Worldwide License Agreement with Centocor Ortho Biotech to Develop and Commercialize RON-Targeted Antibodies

May 31, 2011

CAMBRIDGE, Mass., May 31, 2011 (BUSINESS WIRE) -- AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) today announced it has entered into an exclusive license agreement with Centocor Ortho Biotech Inc. for the worldwide development and commercialization of AVEO's internally-discovered antibodies targeting the RON (Recepteur d'Origine Nantais) receptor. The RON pathway is believed to be involved in several aspects of cancer development including regulation of tumor growth, survival and metastasis, and bone disruption.

TARIS Biomedical Keeps Delivering Drugs Direct-to-the-Bladder

TARIS Biomedical Keeps Delivering Drugs Direct-to-the-Bladder

May 26, 2011

"...That’s where TARIS Biomedical, launched in 2008, comes in to the picture. It is developing a way to deliver a drug directly into the bladder and keep replenishing its supply so the drug can do its job. In a May 16 interview, CEO Sarma Duddu told me that the key to TARIS’s solution is a device, containing the drug, that goes through the urethra like a string of spaghetti and turns into a small pretzel once it gets to the bladder."

Click Forbes logo to view full story.

BG Medicine, Inc.

BG Medicine Announces Achievement of Two Significant Milestones for AMIPredict™

BG Medicine Announces Achievement of Two Significant Milestones for AMIPredict™

May 11, 2011

WALTHAM, Mass., (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) announced today that it has successfully completed an important phase in the development of its AMIPredict™ diagnostic product candidate. AMIPredict is being developed to identify patients with a high risk of suffering heart attack or stroke within the next two to four years. The AMIPredict test is an in vitro diagnostic multivariate index assay that simultaneously measures multiple protein biomarkers in blood.